---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Immunosuppressants and rituximab"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Immunosuppressants and rituximab. Topics: Guideline recommendation when maintenance doses are high, Pooled randomized evidence for immunosuppressants and immunomodulators, Methotrexate versus placebo: corticosteroid or immunoglobulin dose reduction, and Rituximab versus placebo: worsening after immunoglobulin discontinuation. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/immunosuppressants-and-rituximab"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Immunosuppressants and rituximab

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Immunosuppressants and Rituximab

<a id="topic-2.2.2.1.5-1"></a>

### Guideline recommendation when maintenance doses are high

> “(e) if the maintenance dose of any of these is high, consider either combination treatments or adding an immunosuppressant or immunomodulatory drug (Good Practice Point)”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="topic-2.2.2.1.5-2"></a>

### Pooled randomized evidence for immunosuppressants and immunomodulators

> “Four trials fulfilled the selection criteria: one of azathioprine (27 participants), two of IFN beta‐1a (77 participants in total) and one of methotrexate (60 participants).”
> “None of the trials showed significant benefit in any of the outcomes selected by their authors.”
> “None of the trials was large enough to rule out small or moderate benefit.”

Source: [Mahdi-Rogers et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6481566/)

<a id="topic-2.2.2.1.5-3"></a>

### Methotrexate versus placebo: corticosteroid or immunoglobulin dose reduction

> “14 (52%) of 27 taking methotrexate and 14 (44%) of 32 taking placebo had a greater than 20% reduction in mean weekly dose of corticosteroids or intravenous immunoglobulin (adjusted odds ratio 1.21, 95% CI 0.40-3.70).”
> “Oral methotrexate 15 mg weekly showed no significant benefit, but limitations in the trial design and the high rate of response in the placebo group meant that a treatment effect could not be excluded.”

Source: [RMC Trial Group (2009)](https://pubmed.ncbi.nlm.nih.gov/19136303/)

<a id="topic-2.2.2.1.5-4"></a>

### Rituximab versus placebo: worsening after immunoglobulin discontinuation

> “In this randomized, double-blind, placebo-controlled study, conducted at seven Italian hospitals, CIDP patients under immunoglobulin therapy were assigned to receive either rituximab (1 g on Days 1, 15 and 180 ± 7) or placebo.”
> “A similar proportion of patients in both the rituximab (12/19, 63.2%) and placebo (12/18, 66.6%) groups worsened at Month 12 [odds ratio (OR) 0.86; 95% confidence interval (CI) 0.22–3.32].”
> “The median time to worsening was 5 months for rituximab and 2 months for placebo (Log-rank P = 0.4372).”

Source: [Nobile-Orazio et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11967823/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
